

Casgevy (exagamglogene-autotemcel) for Sickle Cell Disease Criteria

Revised: 07/01/2025

CASGEVY (EXAGAMGLOGENE-AUTOTEMCEL) FOR SICKLE CELL DISEASE

Length of Authorization: One treatment course (12 months)

CRITERIA TO APPROVE

Sickle Cell Disease:

All the following:

- Confirmatory genetic testing
- Age 12 years or older
- Prescriber is a specialist at a qualified treatment center for Casgevy
- Patient does not have a contraindication to the prescribed medication
- Patient has history of intolerance or failure of hydroxyurea treatment **or** patient use of hydroxyurea is contraindicated (per provider clinical judgement)
- Clinically stable and fit for transplantation
- Prior to treatment, provider attestation that patient has experienced at least two vaso-occlusive crises per year in the previous twenty-four (24) months, based on provider attestation.

RENEWAL CRITERIA

Not applicable as no further authorizations will be provided

REVISION HISTORY

11/01/2024	• Criteria created
03/28/2025	• Updated “patient experienced at least four vaso-occlusive crises” to at last two vaso-occlusive crises.
06/01/2025	• Clarifications to treatment course (12 months) and additional revisions as requested
07/01/2025	• Updated criteria